London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Gerry557, 13 Mar 2020 10:27
Last post: Gerry557, 13 Mar 2020 10:27
Fallen a tad but much less than the market. It is now lower than the offer price. Is it worth chancing an almost guaranteed 4p gain.
Probably more shares offering better longer term prospects currently on offer. Might have to check the dates of the offer again
Started: Gerry557, 6 Mar 2020 10:53
Last post: Gerry557, 6 Mar 2020 10:54
longs and shorts swapping back ???
With an offer on the table just below this price, who is buying the shares
Interested parties wanting the deal to go ahead? more yes votes accumulated maybe! Markets still red on more CV19 news so just interested why purchases going ahead unless they expect a bidding war of some sort.
Started: Fallingknife1, 3 Mar 2020 08:22
Last post: Gerry557, 3 Mar 2020 11:48
Pity those who bought in the 140's, no chance to get their money back even with divi's.
I think I would vote against the deal personally hoping that it could continue to grow by itself. Results looked good on first glance and I suspect more to come.
Will other come out of the woodwork with a better offer???
Always thought that indicated others interested ?
You can currently sell at a higher price than the 108p offer. No point in waiting for it.
yep, almost certainly taken down imo to make a takeover cheap.
Never understood why this share has been so beaten down until today. I bought at 100p but have been showing mostly a capital loss on it since day one. I only wish I had added more when it fell over the years. It always paid a decent divi which is why I held on but today's update surpasses even my expectations. Certainly turned the corner and then some!
Started: investz, 22 Feb 2020 14:38
Last post: investz, 22 Feb 2020 14:38
See RNS which confirms above.
Started: sharemania, 21 Feb 2020 18:12
Last post: sharemania, 22 Feb 2020 12:04
Putting in a couple of 1000k in here , still researching the history on why it dropped in Share Price.
Yes, I made a small purchase a couple of months ago. Fingers crossed for some well received results in March.
Thanks Beza. are you a share holder, very quite on here , just spotted the trading volume , i'm currently looking at the company accounts .
I’m not sure sharemania. Results are Tues 2nd March. Hopefully they won’t disappoint.
Large Buys 2x £8m , could coronavirus be driving the buying in this stock , please correct me if im wrong ...any share holder.?
Started: 42trader, 24 Jul 2019 09:15
Last post: 42trader, 24 Jul 2019 09:15
Reassuring Results
Huntsworth shares have had a challenging year to date which in our view reflects investor concerns over the growth pause in Marketing, modest cash conversion and H1/H2 phasing. We believe that the group's interim results should provide reassurance in each of these areas. First, a combination of a robust underlying market and the benefits of the group's
strategy coming through will see LFL revenue growth in Marketing accelerate to DCe +10% in H2. Second, after the perfect storm experienced in 2018, cash conversion was 100% in 1H19 and we forecast leverage to fall to 1.6x this year followed by 1.2x in 2020. Finally, the group clearly detailed the £3.5m of investment spent in H1 and how this will drive future revenue growth. Huntsworth has made considerable strategic progress over the past year and has significantly broadened and deepened its product offering. We expect the shares will continue to re-rate as the further evidence of organic revenue growth, cash generation and the synergy benefits from M&A and launch investment come through.
• Interim results. Normalised PBT of £11.4m was ahead of DCe £10.5m.
• Revenues. Group revenues advanced +21% to £123.5m with LFL growth of +3% bolstered by acquisitions. LFL growth was +9% in Medical and Immersive, +1% in Communications and flat in Marketing.
• Adjusted Operating Profit & Margin. Group AOP rose +19% to £14.1m, with margin broadly held at 11.4%. Excluding £3.5m of staff and property investment, underlying margins rose +2.7pts to 14.2%.
• Dividend. Interim DPS was increased +7% to 0.75p, as forecast.
• Balance sheet. Net debt finished the period at £85.8m, considerably better than DCe £92.3m. The group reiterated its guidance for leverage to fall to 'around 1.5x' by the year end.
• Acquisitions. The recent acquisitions of KYNE and Creativ Ceutical are both integrating well and performing to expectations.
• Forecasts. We maintain our FY19 PBT/EPS forecasts of £40.8m/8.6p and view them as underpinned by the better than expected interim results and positive outlook comments.
Started: Gerry557, 23 Jul 2019 09:47
Last post: Gerry557, 23 Jul 2019 09:47
Seem ok. Debt reducing and divi up and more cash in H2
Price spiked a tad on the off but as expected I suppose
Started: 42trader, 10 May 2019 09:22
Last post: 42trader, 10 May 2019 09:22
Huntsworth held an impressive Capital Markets Day yesterday that
comprised detailed presentations from Group Management followed by
senior leadership from Evoke (Marketing) and MEDiSTRAVA (Medical). We
view the key points as i) the global healthcare industry continues to grow
apace with medium/long-term expansion underpinned by demographics
and supported by R&D and innovation ii) Huntsworth is uniquely
positioned to serve this marketplace and continues to target 5-7% organic
revenue growth over the next 5yrs iii) margins are sustainable in Medical
(25%+) and Marketing (23%+) with Immersive set to grow from 14% to
17% over the next 3yrs iv) acquisitions to date have delivered excellent
returns - AboveNation (IRR 28%) and The Creative Engagement Group
(20%), while the group expects strong returns at Giant (13%+) and
Navience (14%+) and v) the Group continues to focus on cash generation
and a leverage target of 'around 1.5x'. We believe the CMD highlighted
the group's robust positioning and attractive fundamentals.
• Market dynamics. Global life expectancy is increasing, with people
aged 60+ set to double to 2bn+ by 2050. This provides a strong
backdrop for the global Healthcare industry, particularly for providers
of prescription drugs that treat chronic diseases. Huntsworth has the
infrastructure to capitalise on the growth in the healthcare marketplace.
• Marketing. We forecast Marketing will generate 42% of Group
revenues and 53% of pre-central cost EBITA in 2019. Reid Connolly
(CEO of Evoke) highlighted the positioning of the enlarged Evoke
Group to offer full-service media strategy, buying, planning and adtech.
After a pause in 2018, the AGM statement indicated Marketing is well
placed to return to growth in 2H19 and into 2020 due to improved new
business and greater collaboration across business units.
• Medical. We forecast Medical will account for 14% and 20% of 2019
Group revenues and pre-central cost EBITA, respectively. The
presentation by Elaine Ferguson (CEO of MEDiSTRAVA) illustrated the
involvement of Medical through the product life cycle. Medical growth
is underpinned by an increase in early phase engagements, rise in Real
World Evidence and growth in demand for consulting projects.
Last post: Gerry557, 11 Mar 2019 08:06
staring in the green on the markets and HNT flat on the off. Well that is an improvement over 5% falls everyday....... but there is still time I here you all cry
Started: Fallingknife1, 7 Mar 2019 15:02
Last post: Gerry557, 9 Mar 2019 12:01
Im not too sure either although I've not been following this too closely since getting out a while back I have been alway last week but left a "cheeky" limit order just in case they dropped further.
They did drop into the order but it looks like it wasnt that cheeky afterall as its dropped a tad further since. Not sure if its the debt levels or just not meeting "expectations" or a major seller getting out.
Hopefully this might start to settle into a more stable range for a while where we can see what the trend is likely to be. It also looks like there is some room for improvement in the figures so if that can bring the debt metrics back into line then things should start to look a lot better.
Anyway back in for the ride again and liked that the divi has increased. Maybe a bit more reading needed
I would say the drop in the sp has stemmed from targets not being met. I’ve failed to find any analyst reports so dont know their figures. Though the results looked good, most of the growth has come inorganically from acquisitions and existing business has not hit their targets partly due to exchange rates.
I have found a short report from 12th december that stated anualised revenues was due to drop 3%.
HNT has a pe ratio of 10 which is actually slightly higher than the industry average of 9.5.
The NAV price is just 48.9p.
Debt has also increased by approx double in the last year.
The large director sell last year would not have helped the sp either.
Hmmm share price dropped off after the results. From a brief glance I can't tell why. I don't like all these restated figures. There is a mention of a cash call or share issue for up to 1-13m? I think this was for a previous acquisition.
One fund reduced after the results. Maybe director leaving not good? Where is the white elephant in the room?
like a stone? Seemed to be well on the way to a recovery but now looks in need of some CPR not to mind PR.
Had alert for this today but missed buying in. Soon turned around from 4.5p down.
Started: Poleaxe, 11 Dec 2018 20:15
Last post: Gotrader, 13 Dec 2018 19:36
Yes statement suggests trading as or bettter than market expects. The net debt is a worry for me but as long as they make money that is good.
RNS today suggest Canaccord Genuity Group Inc still reducing. From 12.3% to 10.99% over the 2 holding RNS. Maybe top slicing their investment here? Someone clearly wanted shares yesterday. Also a lot of automated and or delayed buys yesterday. One assumes they were all buys.
See what happens. Could we see more bigger deals to follow? Maybe pause to let dust settle.
Statement today isn't as bad as yesterday's action suggested. I now thinking a hold rather than a sell!
I wouldn't be surprised to see further growth through acquisition, funded by share issue.
Cannacord reducing? Or lots of level 2 trying to sell? They have made several large purchases here. Have to see if these have paid off.
This news came out today.
https://www.holmesreport.com/latest/article/huntsworth-brings-citigate-grayling-and-red-brands-closer
Citigate is basically moving closer to other brands. Apparently down to leases running out. If they had this much free office space why was this not done sooner? Worth reading above. Maybe markets have read this in the wrong way?
There's been quite a bit of selling in the past week. Folk not wanting to risk holding for trading statement, which must be imminent?
Started: Gotrader, 27 Nov 2018 18:20
Last post: Gotrader, 27 Nov 2018 18:20
Panmure cuts Huntsworth target price to 45p from 54p?
So are they saying Huntsworth is worth half the current share price? Bizarre. It has been drifting a bit lately.
Started: Fallingknife1, 12 Sep 2018 09:28
Last post: Fallingknife1, 12 Sep 2018 09:28
4.8%. You gotta laugh. Only on AIM :)
Started: Investinvalue, 6 Aug 2018 17:45
Last post: Investinvalue, 6 Aug 2018 17:45
to Buy
Started: ahha, 29 Jul 2018 13:42
Last post: Gotrader, 29 Jul 2018 15:50
Yes time to move on for now. Eventually they will have to deal with that debt. Maybe selling on less profitable or struggling units. That being said with their profits they should be able to reduce debts long term.
Agree since they were at 37p they have progressed things here well and given good return for investors. Is this share the best ROI for new investors? Not so sure. If they continue to keeping growing revenue then things could get interesting. Cash is running out without share issues.
I am pleased to see the progress Huntsworth has made over the years......and feel that it was unfortunate that I sold out before the jam appeared on top of the cream! However, I made a nice, if long awaited, profit, so I cannot complain.
My view now is that they have seen the peak for this year. I am also concerned about their increased emphasis on North America. Yes, so far it has proved to be very successful and the devaluation of the pound has also boosted profits in foreign earnings...….but what happens if the dollar starts to sink and the economy there goes pear shaped? I think I will stay out of this share for a while longer and see what happens.
Started: Gotrader, 19 Jul 2018 18:25
Last post: Gotrader, 24 Jul 2018 23:45
Proactive investor suggests :-
' Shares in Huntworth PLC (LON:HNT) sank 9.4% to 120p in late-afternoon trading after the medical communications group reported a net cash outflow despite profit and revenue increases in its interims.
The firm reported a pre-tax profit for the half-year of £10.3mln, up from £9.2mln in the same period last year while revenues climbed to £102.2mln from £94.2mln previously.
However, despite the increases the company recorded a net cash outflow of £1.7mln for the period, a reversal from a £6.4mln cash inflow in the prior year caused primarily by seasonal mixings and a change in the client mix.'
To be fair the share had risen 20-30% recently. I wonder if long term they will just focus on health stuff? More and more of their business is now US based. Has Huntsworth now peaked? See what happens.
Results haven't gone down too well. Is it the increase in debt? Totally transformed company after being in the doldrums for a long time. The fall looks harsh to me.
"This expansion of Huntsworth makes it an even more compelling alternative to the large holding company networks."
'This statement regarding management's views as to the accretive nature of this transaction is not a profit forecast and should not be interpreted to mean that the Group's earnings per share will necessarily match or exceed the historic earnings of the Group.
Huntsworth plc - www.huntsworth.com '
17 July 2018
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014 ("MAR").
17 July 2018
Huntsworth plc
("Huntsworth" or the "Company" or the "Group")
Acquisition of Giant Creative Strategy LLC for a cash consideration of $72.2m
Huntsworth plc, the healthcare and communications group, today announces the acquisition of approximately 90.2% of the membership interests of Giant Creative Holdings, LLC, a limited liability company and parent of Giant Creative Strategy LLC ("Giant") from Shamrock Capital Growth Fund III L.P. and its affiliates and Giant's former and existing management, for a cash consideration of $72.2m funded from existing debt facilities.
Transaction highlights
Giant, based in San Francisco, is one of the largest independent healthcare marketing agencies based on the US west coast. It provides a full service, multichannel offering to its clients in the biopharmaceutical, medical device and diagnostics companies, through its circa 150 staff and derives circa 70% of its revenue from marketing to healthcare professionals ('HCPs'), a key growth area for Huntsworth. When combined with our existing Healthcare marketing agencies led by New York-based Evoke, the Group will be significantly more competitive in responding to changing client demand that is seeking fewer but stronger partners to help access the spectrum of their marketing needs.
Giant's management team is led by founders Steven Gold (CEO) and Adam Gelling (President) who will remain with the business and who hold, along with other senior management, the remaining circa 9.8% of Giant Creative Holdings, LLC's equity which is subject to put and call rights that are exercisable in March of each calendar year commencing in 2021 (the "Put and Call"). The value of the Put and Call will be determined based on a multiple of Giant's earnings over the two-year period prior to exercise of the Put and Call, subject to a cap of $25 million in the aggregate. Consequently, the maximum aggregate consideration payable by Huntsworth for Giant will be $97.2 million. Giant generated revenues of circa $32m and EBITDA of circa $7m in the year to 31 December 2017 and the Group expects the acquisition to be materially accretive to the Group's earnings in the current financial year. Giant's gross assets were $26.1m as at 31 December 2017. Huntsworth is entitled to settle any consideration due under the Put and Call either in cash, by the issue of ordinary shares in the Company ("Shares") or by a mixture of cash and the issue of Shares.
Commenting on the acquisition, Paul Taaffe, Group CEO, said:
"We are delighted to welcome Giant into Huntsworth. Giant is a strong addition to the Group, bringing scale in Healthcare professional ('HCP') marketing especially in the fast growth biotech sector and is led by an outstanding management team who will continue to be invested alongside us in the business.
"This expansion of Huntswort
CORRECTION: " I would NOT put my shirt on these shares"
Regarding RKH ….…..I am nicely in profit as I bought at 25p...…...but I am fairly confident that in 2 or 3 years time these shares will be five times their current price of 35p. I would put my shirt on these shares......but I consider them a fair punt! I also hold CNA...….and think that they are worth getting into.....for a good dividend and share price increase...….especially after a market correction. I think HNT might be worth getting back into.....but probably at around 60 -70p
Looks like a bit of profit taking in last few days. Looks like some of the exisiting fund have decided to reduce here.
You can never call it exactly when to buy or sell.
Yes Gotrader, I pulled out too soon. and I could have bought two very nice new cars with the profit I could have made. But in the past, I have held on too long......with the same results. Now I am retired...….and with the market looking so toppy......I think I made a reasonable decision to take profits. At least I can sleep peacefully at nights. But one is plagued with 'could have' 'should have' thoughts.....I just have to drive them from my mind. I did say that I felt I might live to regret it. I should maybe have sold 2/3rds. We live and learn. But my feeling now is that opportunities to make money in this market are running thin. I think I shall wait for the next roll of the dice.
Started: Gotrader, 18 Jun 2018 18:00
Last post: Gotrader, 18 Jun 2018 18:00
Such a quiet forum but this share keeps surging ahead. I wonder if you should of sold out fully here Ahha? RKH is retracing back to 30p. You could of had 50% more here. That's another 50k. FIL buying too here.
Last post: Gotrader, 6 Jun 2018 18:47
Share above 110p now. Those that bought at 37p have trebled their monies.
Started: Gotrader, 30 May 2018 18:04
Last post: Gotrader, 30 May 2018 18:04
Well I guessed this yesterday based on the number of shares.The Wellcome Trust Limited, as Trustee of The Wellcome Trust has sold all it's shares here. You normally save these kind of RNS to the end of the day.
Started: ahha, 30 May 2018 10:54
Last post: ahha, 30 May 2018 10:54
Brokers predicted �1.07 quite a while ago
Started: ahha, 30 May 2018 01:27
Last post: ahha, 30 May 2018 01:27
Up 5% today. What is going on?
Shares are infuriating. Had I held on I would have got a nice juicy dividend and a better sell price......I sold at 96p but only got 92.5p because it was the best price I could get for selling a large number of shares. I really thought I was ripped off...�.but what can you do? They may go even higher.....but there again the market might pop at any moment. I must be satisfied with the profit I made.
Started: Gotrader, 29 May 2018 18:25
Last post: Gotrader, 29 May 2018 18:25
Seemed to be a reasonable trading update. Healthcare division doing good. Also net debt falling too. More acquisitions on the way. Share shot up to 107p today at one point. 44m shares traded. 16,683,109 is the exact holding of The Wellcome Trust Limited as a Trustee of The Wellcome Trust . Likely they have sold out or switched holding to another trust? Likely other contender is Aberforth Partners LLP? Have to wait for the RNS here. All trades happened at 98.5p so these are all arranged. Gives a strong indication that 98.5p is at least fair value here.
My friend is really bullish on this now. He is not worried about 40p price. He thinks it could go further. Oil price is still rising and is now about 80 dollars. Should of mentioned your share tips to him much sooner. As for HNT I see no reason for this to fall any time soon.
Its been a volatile week! I very much doubt if they will fall below 30p now. And the fundamentals are all in place the...... oil is there. I think by 2020 this share will flourish. And yes, I have no doubt that Trump has engineered an oil rise in accordance with his strategy to promote America and American businessmen. There is some speculation that oil could be �90 by 2020 and remember also that oil shares tend to rise at the close of a bull market.